WEBULL

When Can We Expect A Profit From IceCure Medical Ltd (NASDAQ:ICCM)?

Simply Wall St · 2d ago

IceCure Medical Ltd (NASDAQ:ICCM) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. With the latest financial year loss of US$15m and a trailing-twelve-month loss of US$15m, the US$46m market-cap company alleviated its loss by moving closer towards its target of breakeven. As path to profitability is the topic on IceCure Medical's investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

According to the 2 industry analysts covering IceCure Medical, the consensus is that breakeven is near. They expect the company to post a final loss in 2027, before turning a profit of US$7.6m in 2028. The company is therefore projected to breakeven around 2 years from now. How fast will the company have to grow each year in order to reach the breakeven point by 2028? Working backwards from analyst estimates, it turns out that they expect the company to grow 57% year-on-year, on average, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.

earnings-per-share-growth
NasdaqCM:ICCM Earnings Per Share Growth January 8th 2026

Underlying developments driving IceCure Medical's growth isn’t the focus of this broad overview, though, keep in mind that by and large a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

Check out our latest analysis for IceCure Medical

One thing we’d like to point out is that IceCure Medical has no debt on its balance sheet, which is quite unusual for a cash-burning growth company, which usually has a high level of debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.

Next Steps:

This article is not intended to be a comprehensive analysis on IceCure Medical, so if you are interested in understanding the company at a deeper level, take a look at IceCure Medical's company page on Simply Wall St. We've also put together a list of essential factors you should further examine:

  1. Valuation: What is IceCure Medical worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether IceCure Medical is currently mispriced by the market.
  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on IceCure Medical’s board and the CEO’s background.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.